Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

VRTX - VERTEX PHARMACEUTICALS INC / MA


IEX Last Trade
474.16
0   0%

Share volume: 0
Last Updated: Tue 24 Dec 2024 06:01:13 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 0.45%

PREVIOUS CLOSE
CHG
CHG%

$474.16
-71.61
0.18%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
46%
Profitability 67%
Dept financing 7%
Liquidity 62%
Performance 30%
Company vs Stock growth
vs
Performance
5 Days
2.18%
1 Month
-12.22%
3 Months
-12.47%
6 Months
-14.67%
1 Year
0.00%
2 Year
41.05%
Key data
Stock price
$474.16
P/E Ratio 
-261.26
DAY RANGE
$402.56 - $474.16
EPS 
-$1.88
52 WEEK RANGE
$396.14 - $519.88
52 WEEK CHANGE
-$0.59
MARKET CAP 
127.990 B
YIELD 
N/A
SHARES OUTSTANDING 
258.102 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/04/2024
BETA 
0.57
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$3,532,240
AVERAGE 30 VOLUME 
$1,867,704
Company detail
CEO: Reshma Kewalramani
Region: US
Website: vrtx.com
Employees: 4,800
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial.

Recent news